Edition:
United States

KaloBios Pharmaceuticals Inc (KBIO.OQ)

KBIO.OQ on NASDAQ Stock Exchange Global Market

--USD
--
Change (% chg)

-- (--)
Prev Close
--
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

KBIO.OQ

Chart for KBIO.OQ

About

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company's product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to... (more)
No analyst recommendations are available for KBIO.OQ.

Overall

Beta: 2.77
Market Cap(Mil.): $52.16
Shares Outstanding(Mil.): 14.90
Dividend: --
Yield (%): --

Financials

  KBIO.OQ Industry Sector
P/E (TTM): -- 43.70 36.51
EPS (TTM): -8.63 -- --
ROI: -465.41 -0.32 13.85
ROE: -514.24 -3.00 14.77

BRIEF-Kalobios Pharma says appointed Morgan Lam as chief scientific officer

* Kalobios pharmaceuticals inc says appointed Morgan Lam, formerly chief operating officer of company, as company's chief scientific officer Source text for Eikon: (http://bit.ly/2cUjEff) Further company coverage:

Sep 19 2016

BRIEF-KaloBios Pharmaceuticals announces Martin Shkreli'S sale of his stake in the company

* KaloBios announces Martin Shkreli'S sale of his stake in the company

Aug 29 2016

BRIEF-Martin Shkreli dissolves stake in Kalobios Pharmaceuticals

* Martin Shkreli - sold all shares of Kalobios Pharmaceuticals common stock held on Aug 25, 2016 and Aug 26, 2016 in private transactions

Aug 29 2016

BRIEF-Kalobios Pharmaceuticals files for non-timely 10-Q

* During first half of 2016, co's results of operations impacted by bankruptcy proceedings and operation as debtor-in-possession

Aug 16 2016

BRIEF-KaloBios begins early stage study of leukemia treatment

* KaloBios announces first patient dosed in phase 1 study of Lenzilumab for the treatment of chronic myelomonocytic leukemia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 25 2016

BRIEF-Kalobios Pharmaceuticals says raised $12.2 mln in financing - SEC filing

* Says Raised $12.2 Mln In Equity And Other Financing - SEC filing

Jul 15 2016

BRIEF-Nomis Bay Ltd reports 24.95 pct stake in Kalobios Pharmaceuticals as of June 30 - SEC filing

* Nomis Bay Ltd reports 24.95 percent stake in Kalobios Pharmaceuticals Inc as of June 30 - SEC filing Source text (http://bit.ly/29CFnCE) Further company coverage:

Jul 13 2016

BRIEF-Dale Chappell reports 33.2 pct stake in Kalobios Pharmaceuticals

* Dale Chappell reports 33.2 percent stake in Kalobios Pharmaceuticals inc as of June 30 - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 11 2016

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,845 -13.00
Pfizer Inc. (PFE.N) $33.99 +0.16
Novartis AG (NOVN.S) CHF78.45 -0.10
Roche Holding Ltd. (ROG.S) CHF243.70 -0.90
Roche Holding Ltd. (RO.S) CHF244.20 -0.70
Amgen, Inc. (AMGN.OQ) $169.71 --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.